RT Journal Article
SR Electronic
A1 Kuznar, Wayne
T1 Angiotensin-Neprilysin Inhibitor Could Become a New Standard for HF
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 42
SP 8
OP 9
DO 10.1177/155989771442002
UL http://mdc.sagepub.com/content/14/42/8.abstract
AB Clinical outcomes, including mortality, are improved with the use of a dual angiotensin receptor blocker-neprilysin inhibitor (ARNI), LCZ696, compared with the existing gold standard in the treatment of patients with chronic heart failure (CHF). iscussed findings and insights from a study that evaluated the efficacy and safety of LCZ696 vs enalapril on the morbidity and mortality of patients with CHF-namely, the PARADIGM-HF trial.